

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥(煙台)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

DISCLOSEABLE TRANSACTION PURCHASE OF WEALTH MANAGEMENT PRODUCTS

PURCHASE OF WEALTH MANAGEMENT PRODUCTS

At the 36th meeting held by the second session of the Board on March 27, 2026, a resolution regarding cash management using self-owned funds was considered and approved, pursuant to which the Company may purchase wealth management products using part of idle self-owned funds of not more than RMB2,500.0 million.

As disclosed in the announcement of the Company dated May 14, 2026, on May 14, 2026, the Company entered into (1) the HTSC Wealth Management Product Agreement No. 1 with HTSC, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB60.0 million from HTSC using idle self-owned funds; (2) the HTSC Wealth Management Product Agreement No. 2 with HTSC, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB75.0 million from HTSC using idle self-owned funds; (3) the HTSC Wealth Management Product Agreement No. 3 with HTSC, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB102.0 million from HTSC using idle self-owned funds; and (4) the HTSC Wealth Management Product Agreement No. 4 with HTSC, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB216.0 million from HTSC using idle self-owned funds.

The Board announces that, on May 19, 2026, the Company further entered into (1) the HTSC Wealth Management Product Agreement No. 5 with HTSC, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB15.0 million from HTSC using idle self-owned funds; and (2) the HTSC Wealth Management Product Agreement No. 6 with HTSC, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB20.0 million from HTSC using idle self-owned funds.

LISTING RULES IMPLICATIONS

As the Company entered into (1) the HTSC Wealth Management Product Agreement No. 1, (2) the HTSC Wealth Management Product Agreement No. 2, (3) the HTSC Wealth Management Product Agreement No. 3 and (4) the HTSC Wealth Management Product Agreement No. 4 with HTSC on May 14, 2026 and still holds the wealth management products under such agreements, and the transactions contemplated under (1) the HTSC Wealth Management Product Agreement No. 1, (2) the HTSC Wealth Management Product Agreement No. 2, (3) the HTSC Wealth Management Product Agreement No. 3, (4) the HTSC Wealth Management Product Agreement No. 4, (5) the HTSC Wealth Management Product Agreement No. 5 and (6) the HTSC Wealth Management Product Agreement No. 6 are conducted with the same financial institution and are of similar nature within a 12-month period, for the purpose of calculating the relevant percentage ratios under Rule 14.22 of the Listing Rules, these transactions shall be aggregated in each case as if they were one transaction with the said financial institution.

As one of the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules) in respect of the HTSC Wealth Management Product Agreements (calculated on an aggregation basis with the HTSC Wealth Management Product Agreement No. 1, the HTSC Wealth Management Product Agreement No. 2, the HTSC Wealth Management Product Agreement No. 3 and the HTSC Wealth Management Product Agreement No. 4) exceeds 5% but all of the applicable percentage ratios are less than 25%, the purchase of wealth management products under the HTSC Wealth Management Product Agreements therefore constitutes a discloseable transaction of the Company under Chapter 14 of the Listing Rules and is subject to the reporting and announcement requirements under the Listing Rules.

BACKGROUND

On May 14, 2026, the Company entered into (1) the HTSC Wealth Management Product Agreement No. 1 with HTSC, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB60.0 million from HTSC using idle self-owned funds; (2) the HTSC Wealth Management Product Agreement No. 2 with HTSC, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB75.0 million from HTSC using idle self-owned funds; (3) the HTSC Wealth Management Product Agreement No. 3 with HTSC, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB102.0 million from HTSC using idle self-owned funds; and (4) the HTSC Wealth Management Product Agreement No. 4 with HTSC, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB216.0 million from HTSC using idle self-owned funds.

The Board announces that, on May 19, 2026, the Company further entered into (1) the HTSC Wealth Management Product Agreement No. 5 with HTSC, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB15.0 million from HTSC using idle self-owned funds; and (2) the HTSC Wealth Management Product Agreement No. 6 with HTSC, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB20.0 million from HTSC using idle self-owned funds.

HTSC WEALTH MANAGEMENT PRODUCT AGREEMENTS

The principal terms of the HTSC Wealth Management Product Agreement No. 5 are set out as follows:

Name of product	:	Huatai Ruyi Bao No.10 Collective Asset Management Plan (華泰如意寶10號集合資產管理計劃)
Type of product	:	Fixed-income
Risk rating of product	:	Low-to-medium risk
Principal amount	:	RMB15.0 million
Product subscription date	:	May 19, 2026
Product duration	:	The term of the product shall commence from the observation period commencement date to the third business day following the date falling six months thereafter, and the investors are not allowed to withdraw during the term.
Expected annualized yield rate	:	The performance will fluctuate with the market and is subject to uncertainty.
Right of early termination	:	The administrator shall be entitled to exercise the right of early termination in accordance with the provisions of the agreement.
Investment scope	:	The product proposes to invest in various types of financial instruments lawfully issued, including commercial bank wealth management plans, securities company collective asset management plans, trust plans, bank deposits, money market funds, government bonds, bond reverse repurchase agreements, central bank bills, financial bonds, corporate bonds, bond funds, senior tranches of asset-backed securities, insurance asset management products, yield notes, and over-the-counter options, as well as other financial instruments permitted by the CSRC. The various types of asset management products invested in by the product shall be limited to investments in various standardized assets only.

The principal terms of the HTSC Wealth Management Product Agreement No. 6 are set out as follows:

Name of product	:	Xiamen Trust – Hongyun Xiangtai No.10 Asset Management Trust Product (廈門信託 – 鴻雲祥泰 10 號資產管理信託產品)
Trust Registration System Product Code	:	[ZXD202604210000005699]
Type of product	:	Fixed-Income Collective Fund Trust Plan
Risk rating of product	:	Medium risk

- Principal amount : RMB20.0 million
- Product subscription date : May 19, 2026
- Product investment period : The duration of the product is expected to be 36 months.
- Expected annualized yield rate : The performance will fluctuate with the market and is subject to uncertainty.
- Right of early termination : The trustee shall be entitled to exercise the right of early termination in accordance with the provisions of the agreement.
- Investment scope : The product proposes to invest in consumer loan assets by means of revolving purchase.

The terms of the HTSC Wealth Management Product Agreements were determined upon arm's length negotiations between the parties.

INFORMATION ON THE PARTIES

The Company is a commercial-ready biopharmaceutical company committed to the discovery, development and commercialization of innovative and differentiated biologics for the treatment of autoimmune, oncology and ophthalmic diseases with unmet medical needs in China and globally.

HTSC is a securities company established in the PRC, the A shares and H shares of which are listed on the Shanghai Stock Exchange (stock code: 601688) and the Stock Exchange (stock code: 06886), respectively. HTSC mainly provides financial services, including wealth management, institutional services, investment management and international business.

To the best knowledge, information and belief of the Directors having made all reasonable enquiries, HTSC and its ultimate substantial beneficial owners as publicly disclosed by HTSC are third parties independent from the Company and its connected persons.

REASONS FOR AND BENEFITS OF ENTERING INTO THE HTSC WEALTH MANAGEMENT PRODUCT AGREEMENTS

On the premise of strictly controlling investment risks, the Company intends to fully revitalize idle funds and improve capital utilization efficiency by deploying and managing idle funds through wealth management products. The allocated low-to-medium risk products feature overall controllable risks and yield higher than those of bank time deposits for the same period, which can effectively boost the investment returns on idle funds.

The Directors consider that the terms of the HTSC Wealth Management Product Agreements and the transactions contemplated thereunder are fair and reasonable, on normal commercial terms or better in the ordinary course of business of the Group, and are in the interests of the Company and its Shareholders as a whole.

LISTING RULES IMPLICATIONS

As the Company entered into (1) the HTSC Wealth Management Product Agreement No. 1, (2) the HTSC Wealth Management Product Agreement No. 2, (3) the HTSC Wealth Management Product Agreement No. 3 and (4) the HTSC Wealth Management Product Agreement No. 4 with HTSC on May 14, 2026 and still holds the wealth management products under such agreements, and the transactions contemplated under (1) the HTSC Wealth Management Product Agreement No. 1, (2) the HTSC Wealth Management Product Agreement No. 2, (3) the HTSC Wealth Management Product Agreement No. 3, (4) the HTSC Wealth Management Product Agreement No. 4, (5) the HTSC Wealth Management Product Agreement No. 5 and (6) the HTSC Wealth Management Product Agreement No. 6 are conducted with the same financial institution and are of similar nature within a 12-month period, for the purpose of calculating the relevant percentage ratios under Rule 14.22 of the Listing Rules, these transactions shall be aggregated in each case as if they were one transaction with the said financial institution.

As one of the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules) in respect of the HTSC Wealth Management Product Agreements (calculated on an aggregation basis with the HTSC Wealth Management Product Agreement No. 1, the HTSC Wealth Management Product Agreement No. 2, the HTSC Wealth Management Product Agreement No. 3 and the HTSC Wealth Management Product Agreement No. 4) exceeds 5% but all of the applicable percentage ratios are less than 25%, the purchase of wealth management products under the HTSC Wealth Management Product Agreements therefore constitutes a discloseable transaction of the Company under Chapter 14 of the Listing Rules and is subject to the reporting and announcement requirements under the Listing Rules.

DEFINITIONS

Unless the context otherwise requires, the following terms used herein have the following meanings:

“Board”	the board of Directors
“Company”	RemeGen Co., Ltd.* (榮昌生物製藥(煙台)股份有限公司), a joint stock company incorporated in the PRC with limited liability, the H shares and A shares of which are listed on the Main Board of the Stock Exchange (stock code: 9995) and the Science and Technology Innovation Board of the Shanghai Stock Exchange (stock code: 688331), respectively
“connected person”	has the meaning ascribed to it under the Listing Rules
“CSRC”	the China Securities Regulatory Commission
“Director(s)”	the director(s) of the Company
“Group”	the Company and its subsidiaries
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“HTSC”	Huatai Securities Co., Ltd., a securities company established in the PRC, the A shares and H shares of which are listed on the Shanghai Stock Exchange (stock code: 601688) and the Stock Exchange (stock code: 06886), respectively

“HTSC Wealth Management Product Agreements”	the HTSC Wealth Management Product Agreement No. 5 and the HTSC Wealth Management Product Agreement No. 6
“HTSC Wealth Management Product Agreement No. 1”	the wealth management product agreement entered into between the Company and HTSC dated May 14, 2026 in relation to the purchase of wealth management product in the amount of RMB60.0 million
“HTSC Wealth Management Product Agreement No. 2”	the wealth management product agreement entered into between the Company and HTSC dated May 14, 2026 in relation to the purchase of wealth management product in the amount of RMB75.0 million
“HTSC Wealth Management Product Agreement No. 3”	the wealth management product agreement entered into between the Company and HTSC dated May 14, 2026 in relation to the purchase of wealth management product in the amount of RMB102.0 million
“HTSC Wealth Management Product Agreement No. 4”	the wealth management product agreement entered into between the Company and HTSC dated May 14, 2026 in relation to the purchase of wealth management product in the amount of RMB216.0 million
“HTSC Wealth Management Product Agreement No. 5”	the wealth management product agreement entered into between the Company and HTSC dated May 19, 2026 in relation to the purchase of wealth management product in the amount of RMB15.0 million
“HTSC Wealth Management Product Agreement No. 6”	the wealth management product agreement entered into between the Company and HTSC dated May 19, 2026 in relation to the purchase of wealth management product in the amount of RMB20.0 million
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“PRC” or “China”	the People’s Republic of China excluding, for the purpose of this announcement, Hong Kong, the Macau Special Administrative Region of the People’s Republic of China and Taiwan
“RMB”	Renminbi, the lawful currency of the PRC
“Shareholder(s)”	holder(s) of the shares of the Company

“Stock Exchange” The Stock Exchange of Hong Kong Limited

“%” percent

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and Executive Director

Yantai, the PRC
May 19, 2026

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Lin Jian and Mr. Wen Qingkai as the executive Directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive Directors, and Mr. Hao Xianjing, Mr. Chen Yunjin and Mr. Huang Guobin as the independent non-executive Directors.

* *For identification purpose only*